Stockreport

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF -Contineum is focused on leading the Neuroscience, Inflammation and Immunology (NI&I) field--Successful completion of Initial Public Offering with strong syndicate of ex [Read more]